Table 3.
Post-transplant outcomes for liver and simultaneous liver-kidney recipients by donor HIV status
| Outcomes | HIV D+/R+ (N=24) | HIV D−/R+ (N=21) | p-value |
|---|---|---|---|
| Median follow-up time (months), (IQR) | 18 (12, 24) | 28 (21, 40) | 0.002 |
| Deaths, no. (%) | 6 (25) | 2 (10) | 0.25 |
| Graft failure, no. (%) | 2 (8) | 1 (5)a | >0.99 |
| Recipients with any liver rejectionb, no. (%) | 4 (17) | 4 (19) | >0.99 |
| SLK recipients with any kidney rejection, no. (%) | 1 (33) | 0 (0) | 0.38 |
| Recipients with a SAEa, no. (%) | 15 (68) | 16 (80) | 0.66 |
| Recipients with an infectious hospitalizationa, no. (%) | 8 (36) | 5 (25) | 0.43 |
| Recipients with an opportunistic infection, no. (%) | 6 (25) | 3 (14) | 0.47 |
| Opportunistic infection episodesc, no. | 8 | 3 | 0.049 |
| Pulmonary aspergillosis, no. | 1 | 0 | |
| Candida esophagitis, no. | 0 | 1 | |
| CMV,d no. | 7 | 2 | |
| Recipients with HIV breakthrough, (%) | 2 (8) | 2 (10) | >0.99 |
| Recipients with cancer, no. (%) | 6 (25) | 2 (10) | 0.25 |
| Bowen’s disease (squamous cell carcinoma in situ), no. | 1 | 0 | |
| Kaposi’s sarcoma and/or HHV8-related lymphoma,e no. | 3 | 0 | |
| Myoepithelial carcinoma of right parotid gland, no. | 1 | 0 | |
| Anal cancer, no. | 1 | 0 | |
| Recurrent hepatocellular carcinoma, no. | 0 | 2 |
1 D− recipient experienced hepatic artery thrombosis immediately post-transplant and was re-transplanted at day 30
11 episodes among 8 recipients, 5 episodes in D+/R+ (1 SLK recipient had both a kidney and liver rejection); 6 episodes in D+/R−
2 D+ and 1 D− recipients transplanted after SAE censorship date 1/24/19 were excluded from this analysis
p-value obtained using unweighted negative binomial regression
9 episodes among 7 recipients, 2 HIV D+ recipients had 2 episodes each; 6 (5 HIV D+, 1 HIV D−) of 7 recipients were CMV D+/R−; 7 episodes of CMV viremia without end-organ disease, 2 episodes of probable CMV colitis
Among 2 D+: 1 episode of cutaneous-only KS treated with sirolimus, 2 with visceral disease treated with chemotherapy.
1 D+ recipient with Kaposi’s sarcoma of skin, 1 D+ recipient with Kaposi’s sarcoma of liver and lung, 1 D+ recipient with HHV8-related diffuse large B cell lymphoma and Kaposi’s sarcoma of lymph nodes
CMV, cytomegalovirus; SAE, serious adverse event; SLK, simultaneous liver-kidney transplant.